World's Best Scientists 2026 revealed!
Richard S.E. Keefe

Richard S.E. Keefe

D-Index & Metrics

Medicine

D-Index
112
Citations
57300
World Ranking
5076
National Ranking
2747

Overview

Richard S.E. Keefe is affiliated with Duke University in the United States. Their research primarily spans the field of Medicine, with a particular focus on Psychiatry and Mental Health. Other subfields include Cognitive Neuroscience, Experimental and Cognitive Psychology, Clinical Psychology, and Philosophy.

Their work addresses several main topics including schizophrenia research and treatment, functional brain connectivity studies, mental health research topics, dementia and cognitive impairment research, mental health and psychiatry, bipolar disorder and treatment, and stroke rehabilitation and recovery.

Keefe has published extensively in a range of venues. Frequent publication sources include UNC Libraries, Schizophrenia Research, Schizophrenia Research Cognition, JAMA Psychiatry, and the American Journal of Psychiatry.

The scientist has collaborated frequently with several co-authors such as Diana O. Perkins, Jeffrey A. Lieberman, Philip D. Harvey, T. Scott Stroup, and Matcheri S. Keshavan.

Selected recent papers authored or co-authored by Richard S.E. Keefe illustrate the breadth of their research interests:

  • Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment (2023, Molecular Psychiatry)
  • A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial (2020, The Lancet Digital Health)
  • A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020, Nature Medicine)
  • Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study (2021, The Lancet Psychiatry)
  • Antipsychotic Drugs and Cognitive Function (2024, JAMA Psychiatry)

Best Publications

  • Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

    Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz

  • The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

    Keith H. Nuechterlein;Michael F. Green;Robert S. Kern;Lyle E. Baade

  • Persistent cannabis users show neuropsychological decline from childhood to midlife

    Madeline H. Meier;Avshalom Caspi;Antony Ambler;Antony Ambler;Hona Lee Harrington

  • The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

    Richard S.E Keefe;Terry E Goldberg;Philip D Harvey;James M Gold

  • Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

    Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey

  • Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

    Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis

  • Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria

    Michael F. Green;Keith H. Nuechterlein;James M. Gold;M Deanna

  • The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis

    Richard S.E. Keefe;Susan G. Silva;Diana O. Perkins;Jeffrey A. Lieberman

  • Antipsychotic drug effects on brain morphology in first-episode psychosis

    Jeffrey A. Lieberman;Jeffrey A. Lieberman;Gary D. Tollefson;Cecil Charles;Robert Zipursky

  • The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

    Robert S. Kern;Keith H. Nuechterlein;Michael F. Green;Lyle E. Baade

  • Schizophrenia Is a Cognitive Illness: Time for a Change in Focus

    René S. Kahn;Richard S. E. Keefe

  • Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

    Philip D. Harvey;Richard S.E. Keefe

  • Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.

    Abraham Reichenberg;Avshalom Caspi;HonaLee Harrington;Renate Houts

  • Barriers to Employment for People With Schizophrenia

    Robert Rosenheck;Douglas Leslie;Richard Keefe;Joseph McEvoy

  • Cognitive Impairment in Schizophrenia

    Richard S. E. Keefe;Philip D. Harvey

  • Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

    Richard S.E. Keefe;Robert M. Bilder;Philip D. Harvey;Sonia M. Davis

  • A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia

    Robert W Buchanan;Miriam Davis;Donald Goff;Michael F Green

  • Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

    T. Scott Stroup;Jeffrey A. Lieberman;Joseph P. McEvoy;Marvin S. Swartz

  • A genome-wide investigation of SNPs and CNVs in schizophrenia

    Anna C. Need;Dongliang Ge;Michael E. Weale;Jessica Maia

  • How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?

    Richard S. E. Keefe;Wayne S. Fenton

Frequent Co-Authors

Philip D. Harvey
Philip D. Harvey University of Miami
Jeffrey A. Lieberman
Jeffrey A. Lieberman Columbia University
Joseph P. McEvoy
Joseph P. McEvoy Augusta University
Kenneth L. Davis
Kenneth L. Davis Icahn School of Medicine at Mount Sinai
Diana O. Perkins
Diana O. Perkins University of North Carolina at Chapel Hill
Larry J. Siever
Larry J. Siever Icahn School of Medicine at Mount Sinai
James M. Gold
James M. Gold University of Maryland, Baltimore
Michael F. Green
Michael F. Green University of California, Los Angeles
Marvin S. Swartz
Marvin S. Swartz Duke University
Robert A. Rosenheck
Robert A. Rosenheck Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in the broader healthcare field or looking to expand their qualifications alongside or instead of a medical degree, online programs offer excellent flexibility. One popular option is a healthcare administration accelerated degree, which can fast-track your career into leadership roles within hospitals and clinics.

Nursing professionals may consider the adn to np bridge programs, which allow registered nurses to progress to nurse practitioner roles more efficiently. These pathways are designed for working nurses seeking to advance without stepping away from their current roles.

If nutrition and wellness are your calling, a nutrition degree online provides foundational and advanced knowledge that can open doors to clinical or community-based positions.

Those pursuing upper-level management careers can benefit from exploring the best mha programs. Such credentials are highly regarded and can offer a competitive edge for leadership roles in various healthcare settings.

Best Scientists Citing Richard S.E. Keefe

Trending Scientists

Recently Published Articles